Navigation Links
Pixantrone Granted Fast Track Designation by FDA for Relapsed,Indolent NHL Patients

Proposed Phase III Trial Has the Potential to Demonstrate an Effect on a Serious or Life Threatening Aspect of This Disease

SEATTLE, May 07, 2007 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) announced today it received fast track designation from the U.S. Food and Drug Administration (FDA) for pixantrone, a novel anthracenedione, being investigated for the potential treatment of relapsed or refractory indolent non-Hodgkin's lymphoma (NHL). In granting fast track, the FDA noted that "relapsed or refractory indolent NHL is a serious and life threatening condition and is generally considered incurable. Results from a phase I and phase III study in patients with relapsed and/or refractory indolent non-Hodgkin's lymphoma suggest that pixantrone is active in this disease." The FDA also noted that the proposed phase III trial in combination with fludarabine and rituximab "has the potential to demonstrate an effect on a serious or life threatening aspect of this disease."

Prior results demonstrated that the addition of pixantrone to a fludarabine/rituximab-based regimen in relapsed or refractory indolent NHL yielded a 70 percent confirmed response/unconfirmed response (CR/uCR) rate. In that phase I/II study the estimated median duration of response was 25 months (range 2.3 to 43 months) and the estimated progression-free survival (PFS) rate at three years was 50.4 percent. A phase III trial of rituximab compared to rituximab plus pixantrone in relapsed or refractory indolent NHL had a 61 percent overall improvement in time to tumor progression (TTP) compared to rituximab alone (395 days vs. 245 days). In that randomized trial, the median TTP estimate for pixantrone/rituximab was 13.2 months compared to 8.1 months for rituximab alone (hazard ratio 0.13, log rank p< 0.001). The overall response rate in the pixantrone/rituximab arm was 75 percent versus 33 percent in the rituximab arm with a CR rate of 30 percent in the pixantrone/rituximab arm versus 11 p
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
4. Allos Therapeutics PDX Granted Orphan Medicinal Product Designation by the European Commission
5. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Stanford Researchers Track Human Stem Cells Transplanted Into Rat Brain
8. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
9. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
10. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
11. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
Post Your Comments:
(Date:5/20/2013)... , May 20, 2013 A medical ... use both in space and on Earth was inducted ... The technology assures high quality, secure handling ... low-power ultrasound units, like those used in hospitals and ... the diagnostic imaging solution of choice for human space ...
(Date:5/20/2013)... VIEJO , Kalifornien, 20. Mai 2013 ... bekannt, dass das Unternehmen die CE-Kennzeichnung für ... zur Embolisation von Aneurysmen erhalten hat. Das ... Europa bereits mit der kontrollierten Einführung dieser ... bietet die SL-Produktfamilie auch ein verbessertes Handling, ...
(Date:5/20/2013)... ATLANTA , May 20, 2013  Atlantic ... developed and is commercializing a unique technology to ... founder and President, Anthony Soscia ... the Atlanta Business Chronicle ,s Health-Care Heroes ... Atlanta Business Chronicle to honor individuals and ...
Breaking Medicine Technology:Wyle Aided System Gets Named to Space Technology Hall of Fame 2Wyle Aided System Gets Named to Space Technology Hall of Fame 3Sequent Medical, Inc. bringt neue SL-Produktfamilie seiner WEB Geräte zur Embolisation von Aneurysmen auf den Markt 2Sequent Medical, Inc. bringt neue SL-Produktfamilie seiner WEB Geräte zur Embolisation von Aneurysmen auf den Markt 3Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology 2
(Date:5/21/2013)... IL (PRWEB) May 21, 2013 The ... on the site for patients taking the blood thinner ... may be at more risk of death when suffering ... DrugRisks was created to improve the safety of patients ... recalls, studies and legal news. Visitors can see if ...
(Date:5/21/2013)... Limited mobility affects people in ways that the ... difficult to walk around, but everyday tasks like getting up ... of medical products made to assist those who need a ... seat. , Raised toilet seats keep users further ... or sit down. They come in a variety of sizes ...
(Date:5/20/2013)... was significantly associated with higher hyperactivity scores at ... University of Cincinnati (UC) and Cincinnati Children,s Hospital ... a study being published Tuesday, May 21, in ... access journal published by the National Institute of ... Institutes of Health (NIH). , The research ...
(Date:5/20/2013)... (PRWEB) May 21, 2013 The ... product type into two categories - semi-automated and ... is classified into five categories, namely, hospitals, pre-hospital, ... is forecast till 2017. Automated external defibrillators play ... sudden cardiac arrest victims. Considering the life-saving potential ...
(Date:5/20/2013)... 2013 When people have ... to become a celebrity. New Jersey governor Chris ... News report (“Chris Christie Says Lap Band Surgery ... the surgery was not done so that he ... status as a former lap band patient. Simply ...
Breaking Medicine News(10 mins):Health News:DrugRisks Update: New Study Warns of Pradaxa Brain Bleeding 2Health News:JustHomeMedical.com Launches Raised Toilet Seats Category 2Health News:Early-life traffic-related air pollution exposure linked to hyperactivity 2Health News:North America Leads Automated External Defibrillator Market (AED), Says New Research Report at ReportsnReports.com 2Health News:North America Leads Automated External Defibrillator Market (AED), Says New Research Report at ReportsnReports.com 3Health News:The Lap Band Center: Dr. Atul Madan Applauds Chris Christie's Dedication to Family and Loss of 30 Pounds After Lap Band Surgery 2Health News:The Lap Band Center: Dr. Atul Madan Applauds Chris Christie's Dedication to Family and Loss of 30 Pounds After Lap Band Surgery 3
... carcinoma (HCC) patients in China may be treated with ... doubt its effectiveness. These stated that a research group ... of PTEN in HCC, which may suppress tumor cell ... A research article published on January 7, 2008 ...
... A procedure called carotid artery stenting (CAS) has ... carotid endarterectomy (CEA), for patients with dangerous narrowing of ... questions remain about the best uses of this procedureespecially ... "low-risk" patients, according to a special article in the ...
... 2008A research team from Universit Lavals Faculty of Medicine ... by the use of antipsychotic drugswhich in extreme cases ... one monthcan be avoided through a specially designed weight ... and kinesiologist Angelo Tremblay report the details of their ...
... team of Tchernev and Petrova from Alexandrovska Hospital in ... by chronic Hepatitis C virus (HCV). They were intrigued ... on the lower limbs, acute pain in the joints, ... They were also intrigued by the presence of cryoglobulins ...
... digestive enzyme specifically produced in the gastric mucosa. Human ... immunological properties, PGI and PGII. Serum PG levels seem ... in the stomach, and used as "serological biopsy." In ... on the identification of individuals for intervention studies, whereas ...
... for treatment of patients with chronic hepatitis B ... leads to the emergence of lamivudine-resistant hepatitis B ... with HBV. Sensitive methods for early detection of ... in treating patients with HBV infection. , To ...
Cached Medicine News:Health News:How does Fu-Zheng-Jie-Du-Decoction act on PTEN expression in hepatocellular carcinoma? 2Health News:Vascular surgeons ask, what's next for carotid artery stenting? 2Health News:Weight gain induced by antipsychotic drugs can be avoided 2Health News:Attention: Extra-hepatic manifestation of hepatitis C virus infection 2Health News:What are the essential characteristics of serum PG in Chinese? 2Health News:What is the more suitable for early detection of low abundant lamivudine-resistant mutants? 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: